{"id":"W2559562829","doi":"10.1016/s1470-2045(16)30558-7","title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","year":2016,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Polycythaemia; Ruxolitinib; Internal medicine; Polycythemia vera; Clinical endpoint; Myeloproliferative neoplasm; Randomized controlled trial; Pediatrics; Myelofibrosis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00182746,0.0003312516,0.002129402,0.00006940554,0.0002769345,0.00002726438,0.0003859474,0.0001000659,0.0001883975],"category_scores_gemma":[0.000582151,0.0001194491,0.0001847017,0.0001090736,0.000240175,0.00005205218,0.00006370582,0.00009232567,0.00003064182],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004614473,"about_ca_system_score_gemma":0.0005513899,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000172807,"about_ca_topic_score_gemma":0.000185701,"domain_scores_codex":[0.9972633,0.0009768902,0.0006560535,0.0003918602,0.0002141168,0.0004978315],"domain_scores_gemma":[0.989439,0.009074833,0.0004085587,0.0007774513,0.0001728253,0.0001273719],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9003091,0.01888389,0.01000255,0.00001939407,0.003543913,0.0001042231,0.003006375,0.000001332201,0.00376391,0.001417787,0.002090875,0.05685668],"study_design_scores_gemma":[0.8149011,0.06080186,0.008061018,0.00005437591,0.001876129,0.00006475882,0.0005275814,0.00008398751,0.003660789,0.0001811237,0.1096324,0.0001548848],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9412561,0.001110834,0.0001323565,0.04020238,0.0002391644,0.0155641,0.0001956685,0.00003343921,0.001265945],"genre_scores_gemma":[0.9842039,0.001253796,0.0003227449,0.00117163,0.0005380358,0.01000426,0.00001101573,0.00003602916,0.002458525],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1075415,"threshold_uncertainty_score":0.4870995,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1614760596358667,"score_gpt":0.4526537947164275,"score_spread":0.2911777350805609,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}